A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients [0.03%]
基于美国医疗图表的常见FVIII产品的实际分析：消耗和血友病A患者的出血结果
Songkai Yan,Géraldine S Maro,Vidhi Desai et al.
Songkai Yan et al.
Background: Patients with hemophilia A are commonly treated with replacement recombinant factor VIII (rFVIII) products, which can be standard-acting or long-acting. Long-acting products have modifications, offering the po...
AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement [0.03%]
AMCP合作伙伴论坛：专科药品福利设计和偿付的下一步方向是什么？
Rising specialty drug costs present a challenge for patients and payers. High-cost products, such as gene therapies or immunotherapies, can significantly affect the budget of a payer that does not have the ability to spread risk across a la...
The Authors Respond [0.03%]
作者回应
Christina H Sherrill,Christopher T Houpt,Elisabeth M Dixon et al.
Christina H Sherrill et al.
No outside funding supported this study. The authors have nothing to disclose.
A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative [0.03%]
运用真实世界数据和美国食品药品监督管理局的Sentinel计划跟踪评价仿制药质量的倡议
Joshua D Brown
Joshua D Brown
The author reports funding from the U.S. Food and Drug Administration to study real-world data approaches to detect generic drug quality issues. There are no further conflicts or disclosures.
Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data [0.03%]
基于真实世界美国数据的类风湿关节炎使用靶向免疫调节药物的有效性和成本研究
Mahdi Gharaibeh,Machaon Bonafede,Donna McMorrow et al.
Mahdi Gharaibeh et al.
Background: Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic and nonbiologic medications with different mechanisms of action. Data describing...
Editor's Note [0.03%]
编者按
Laura E Happe
Laura E Happe
Flash Continuous Glucose Monitoring in Primary Care Settings: The Need for Measurement of Novel Glycemic Metrics to Adopt Policy and Practice Change [0.03%]
基层医疗环境中的持续葡萄糖监测：制定政策和实践改变以采用新型血糖指标的必要性
Kevin Cowart
Kevin Cowart
No outside funding supported the writing of this letter. The author has nothing to disclose.
Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care [0.03%]
预测难治性抑郁发作的发生：一种面向医疗保健系统的模型
Joshua N Liberman,Tigwa Davis,Jacqui Pesa et al.
Joshua N Liberman et al.
Background: Major depressive disorder (MDD) is a prevalent and debilitating condition. While numerous treatment options are available, low treatment response and high remission rates remain common, leading to the concept ...
Kim A Caldwell,Babette Edgar
Kim A Caldwell
No funding supported the writing of this commentary. The authors have nothing to disclose.
Optimization of Lipid-Lowering Therapy for High Cardiovascular Risk Patients Through Electronic Medical Record Reporting and Pharmacist Evaluation [0.03%]
基于电子病历报告和药师评估的高危心血管风险患者降脂治疗优化措施研究
Kaylee Chen,Scott Canfield,Joshua Blackwell et al.
Kaylee Chen et al.
Background: Identification of high cardiovascular risk patients on suboptimal lipid-lowering therapy (LLT) may be possible through electronic medical record (EMR) reporting, presenting an opportunity for pharmacist involv...